¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"cell death"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
  • killer cell
    »ìÇØ¼¼Æ÷
  • Langerhans cell
    ¶û°Ô¸£Çѽº¼¼Æ÷
  • Langerhans cell histiocytosis
    ¶û°Ô¸£Çѽº¼¼Æ÷Á¶Á÷±¸Áõ
  • large cell acanthoma
    Å«¼¼Æ÷°¡½Ã¼¼Æ÷Á¾, ´ë¼¼Æ÷±Ø¼¼Æ÷Á¾
  • large cell carcinoma
    ´ë¼¼Æ÷¾ÏÁ¾, Å«¼¼Æ÷¾ÏÁ¾
  • lepra cell
    ³ªº´¼¼Æ÷
  • leukemic cell
    ¹éÇ÷º´¼¼Æ÷
  • Leydig cell tumor
    ¶óÀ̵ðÈ÷¼¼Æ÷Á¾¾ç
  • light cell
    ¹àÀº¼¼Æ÷
  • lipoid cell
    ÁöÁú¼¼Æ÷
  • luteal cell
    Ȳ(»ö)ü¼¼Æ÷
  • lymphoid cell
    ¸²ÇÁ°è¼¼Æ÷, ¸²ÇÁ¸ð¾ç¼¼Æ÷
  • lymphokine-activated killer cell
    ¸²Æ÷Ä«ÀÎȰ¼º»ìÇØ¼¼Æ÷
  • lymphopoietic cell
    ¸²ÇÁ±¸Çü¼º¼¼Æ÷
  • lymphosarcoma cell leukemia
    ¸²ÇÁÀ°Á¾¼¼Æ÷¹éÇ÷º´
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
  • myoid cell
    À¯»ç±ÙÀ°¼¼Æ÷
  • natural killer cell
    ÀÚ¿¬¼¼Æ÷µ¶¼º¼¼Æ÷, ÀÚ¿¬¼¼Æ÷µ¶¼º¼¼Æ÷
  • nerve cell
    ½Å°æ¼¼Æ÷
  • neural crest cell
    ½Å°æ´É¼±¼¼Æ÷
  • neuroendocrine cell
    ½Å°æ³»ºÐºñ¼¼Æ÷
  • neuroepithelial cell
    ½Å°æ»óÇǼ¼Æ÷
  • neuroglial cell
    ½Å°æ¾Æ±³¼¼Æ÷
  • neurosecretory cell
    ½Å°æºÐºñ¼¼Æ÷
  • nevus cell
    ¸ð¹Ý¼¼Æ÷
  • nodal cell
    °áÀý¼¼Æ÷
  • nucleated cell
    À¯ÇÙ¼¼Æ÷
  • null cell
    ¹«Ç¥Áö¼¼Æ÷
  • nurse cell
    (¢¡supporting cell) ¹öÆÀ¼¼Æ÷
  • oat cell carcinoma
    ±Í¸®¼¼Æ÷¾ÏÁ¾
  • osmiophilic cell
    Ä£¿À½º¹Å¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
  • hypersensitivity reactions,type ii(antibody-dependent cell-mediate cyt
    IIÇü
  • hypersensitivity reactions,type iv(cell-mediated)
    IVÇü
  • hypersensitivity, cell-mediated
    ¼¼Æ÷¸Å°³ °ú¹Î¹ÝÀÀ
  • hypersensitized cell
    °ú°¨ÀÛ¼¼Æ÷.
  • hypoglycemia, beta cell tumor
    ÀúÇ÷´ç(Áõ), º£Å¸¼¼Æ÷Á¾
  • hypoxic cell
    Àú»ê¼Ò¼¼Æ÷
  • hypoxic cell sensitizer
    Àú»ê¼Ò¼¼Æ÷°¨ÀÛÁ¦
  • i-cell disease
    I-¼¼Æ÷º´
  • idiotype specific regulatory cell
    °³º°Æ¯ÀÌÇü Á¶Àý¼¼Æ÷
  • immortalized cell
    ¹«ÇÑÁõ½Ä¼¼Æ÷
  • immunity,cell-mediated
    ¼¼Æ÷¸Å°³¼º(á¬øàØÚË¿àõ)
  • immunocompetent cell
    ¸é¿ªÀû°Ý¼¼Æ÷.
  • immunodeficiency syndrome, cell mediated
    ¼¼Æ÷¸Å°³ ¸é¿ª°áÇÌ ÁõÈıº
  • immunologically committed cell
    ¸é¿ª°æÇè¼¼Æ÷(¡­ÌèúÐá¬øà).
  • immunologically competent cell
    ¸é¿ªÀû°Ý¼¼Æ÷(¡­îêÌ«á¬øà).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
  • cell injury
    ¼¼Æ÷¼Õ»ó(¡­áßß¿)
  • cell interaction
    ¼¼Æ÷»óÈ£ÀÛ¿ë
  • cell interface
    ¼¼Æ÷»çÀ̸é, ¼¼Æ÷°£¸é (¡­ÊàØü).
  • cell junction
    ¼¼Æ÷°£¿¬Á¢(á¬øàÊàææïÈ)(°áÇÕ)
  • cell junction
    ¼¼Æ÷°æ°è, ¼¼Æ÷¿¬Á¢(¡­ææïÈ).
  • cell killing
    ¼¼Æ÷»ìÇØ
  • cell labelling technique
    ¼¼Æ÷Ç¥Áö±â¹ý
  • cell lethality
    ¼¼Æ÷Ä¡»çÀ²
  • cell like colloidal drop
    ¼¼Æ÷¾çÄÝ·ÎÀ̵å¾×Àû.
  • cell line
    ¼¼Æ÷°è, ¼¼Æ÷ÁÖ
  • cell line
    ¼¼Æ÷°è(á¬øàͧ).
  • cell line
    ¼¼Æ÷°è(á¬øàͧ).
  • cell line, established
    È®¸³¼¼Æ÷ÁÖ
  • cell loss
    ¼¼Æ÷¼Ò½Ç
  • cell loss factor
    ¼¼Æ÷¼Ò½Ç°è¼ö
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 19
CDC calculated date of confinement; cancer diagnosis center; capillary diffusion capacity; cell division...
CI cardiac index; cardiac insufficiency; cell immunity; cell inhibition; cephalic index; cerebral infar...
CMI carbohydrate metabolism index; care management integration; case mix index; cell-mediated immunity; ...
CML carboxymethyl lysine; cell-mediated lymphocytotoxicity; cell-mediated lympholysis; central motor lat...
FDC factor-dependent cell [line]; follicular dendritic cell
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 19
BCC Basal Cell Carcinoma
BCNS Basal Cell Nevus Syndrome
BCE Basal cell epithelioma
BCH Basal cell hyperplasia
BSCC Basaloid squamous cell carcinoma
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • parietal cell
    º® ¼¼Æ÷, ¿Üº® ¼¼Æ÷, º®Ãø ¼¼Æ÷
    1. À§ÀåÀÇ À§Ã¼¹«¿¡ ÀÖ´Â ¼±ÀÇ neck°ú isthmus¿¡ ¸¹ÀÌ ºÐºñÇϸç, ¿°»êÀ» ºÐºñÇÑ´Ù. 2. À§¾× Áß ¿°»êÀÇ ¿øÃµÀÌ µÇ´Â Å« Ÿ¿ø»ó ¶Ç´Â Ãßü»óÀÇ ¼¼Æ÷. À§¼± º®À» µû¶ó »êÀçÇϰí, °¡´Ã¾îÁø ¾ç´ÜÀº ÁÖ¼¼Æ÷ »çÀÌ¿¡ ³¢¾î ÀÖ´Ù.
  • pericellular cell
    ¼¼Æ÷ ÁÖÀ§ ¼¼Æ÷
  • perineural cell
    ½Å°æ ÁÖÀ§ ¼¼Æ÷
  • peritoneal exudate cell
    º¹°­ »ïÃâ ¼¼Æ÷
  • peritubal cell
    À̰ü ÁÖÀ§ ºÀ¼Ò
  • perivascular cell
    Ç÷°ü ÁÖÀ§ ¼¼Æ÷
  • phagocytic synovial cell
    Æ÷½Ä À±È° ¼¼Æ÷
  • physiological cell
    »ý¸® ¼¼Æ÷
  • pigment cell nevus
    »ö¼Ò ¼¼Æ÷ ¸ð¹Ý
  • plasma cell
    ÇüÁú±¸, Ç÷Àå ¼¼Æ÷, ÇüÁú ¼¼Æ÷
    1. Ç×ü¸¦ ºÐºñÇÒ ¼ö ÀÖ´Â ¼¼Æ÷. 2. ¸¸¼º ¿°ÁõÀ̳ª ƯÁ¤ Áúȯ »óÅÂ, ¶Ç´Â Á¾¾ç¿¡¼­ ³ªÅ¸³ª´Â ¼¼Æ÷·Î ¼øÈ¯ Ç÷¾×¿¡ Á¤»óÀûÀ¸·Î ³ªÅ¸³ªÁö´Â ¾Ê´Â´Ù. Å©±â´Â Àӯı¸º¸´Ù Å©¸ç, È£¿°±â¼ºÀÇ ¿°»öÁúÀ» °¡Áö´Â ÇÙÀÌ ¼¼Æ÷ÀÇ Á߽ɿ¡¼­ ¹þ¾î³ª ½Ã°èÀÇ ¼ýÀÚÆÇÀÇ ¼ýÀÚµéó·³ º¯¿¬¿¡ À§Ä¡Çϰí ÀÖ´Ù. ÀÌ ¼¼Æ÷ÀÇ ±â¿ø¿¡ °üÇØ¼­´Â
  • plasma cell dyscrasia
    Ç÷Àå ¼¼Æ÷ ÀÌ»ó
  • plasma cell pneumonia
    ÇüÁú ¼¼Æ÷¼º Æó·Å
  • pleomorphic cell
    ´ÙÇü ¼¼Æ÷
  • pluripotential stem cell
    ´Ù´É¼º °£ ¼¼Æ÷
  • PNH cell
    PNH ¼¼Æ÷
    ¹ßÀÛ¼º ¾ß°£ Ç÷»ö´¢Áõ¿¡¼­ º¸ÀÌ´Â ÀûÇ÷±¸. ÀÌµé ¼¼Æ÷´Â Á¤»ó ¶Ç´Â Á¤»ó À¯»ç ¼¼Æ÷
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
renal cell carcinoma <oncology, tumour> The most common form of kidney cancer which occurs when the cells lining the renal tubule undergo cancerous changes. There are approximately 18,000 new cases of renal cell carcinoma (hypernephroma) per year in the U.S. With about 8,000 deaths annually.
Smoking is considered a major risk factor. Kidney dialysis patients are at increased risk for the development of hypernephroma. Family history for renal cell carcinoma is also considered a risk factor.
Symptoms include haematuria, flank pain, abdominal pain, back pain, weight loss and abdominal swelling.
(27 Sep 1997)
cell bridges Slender cytoplasmic strands connecting adjacent cells; in histological sections of the epidermis and other stratified squamous epithelia, the bridge's are processes attached by a desmosome and are shrinkage artifacts of fixation; true bridge's with cytoplasmic confluence exist between incompletely divided germ cells.
Synonym: cell bridges, cytoplasmic bridges.
(05 Mar 2000)
cell centre Microtubule organising centre of the cell, the pericentriolar region.
(18 Nov 1997)
cell cloning The process of producing a group of cells (clones), all genetically identical, from a single ancestral cell.
(12 Dec 1998)
cell communication Any of several ways in which living cells of an organism communicate with one another, whether by direct contact between cells or by means of chemical signals carried by neurotransmitter substances, hormones, and cyclic AMP.
(12 Dec 1998)
cell compartmentation A partitioning within cells due to the selectively permeable membranes which enclose each of the separate parts, e.g., mitochondria, lysosomes, etc.
(12 Dec 1998)
cell count A count of the number of cells of a specific kind, usually measured per unit volume of sample.
(12 Dec 1998)
cell culture General term referring to the maintenance of cell strains or lines in the laboratory.
(18 Nov 1997)
cell cycle <cell biology, molecular biology> The sequence of events between mitotic divisions. The cycle is conventionally divided into G0, G1, (G standing for gap), S (synthesis phase during which the DNA is replicated), G2 and M (mitosis).
Cells that will not divide again are considered to be in G0 and the transition from G0 to G1 is thought to commit the cell to completing the cycle and dividing.
(26 Mar 1998)
cell cycle proteins Proteins that control the cell division cycle. This family of proteins includes a wide variety of classes, including cyclin-dependent kinases, mitogen-activated kinases, cyclins, and phosphoprotein phosphatases (phosphoprotein phosphatase) as well as their putative substrates such as chromatin-associated proteins, cytoskeletal proteins, and transcription factors.
(12 Dec 1998)
cell cycle restriction point <cell biology, molecular biology> A point, late in G1, after which the cell must, normally, proceed through to division at its standard rate.
(26 Mar 1998)
cell degranulation The process of losing cytoplasmic granules. This occurs in mast cells, basophils, neutrophils, eosinophils, and platelets when secretory products are released from the granules.
(12 Dec 1998)
cell determination The process by which embryonic cells, previously undifferentiated, take on a specific developmental character.
Although the mechanism is not fully understood, homeotic proteins coded for by certain gene sequences (the homeobox) appear to trigger the process. Genes for homeotic proteins show remarkable similarity among species.
See: morphogenesis, induction, evocator.
(05 Mar 2000)
cell differentiation Progressive restriction of the developmental potential and increasing specialization of function which takes place during the development of the embryo and leads to the formation of specialised cells, tissues, and organs.
(12 Dec 1998)
cell disruption <technique> The procedures used to get genetically engineered products out of the cells in which they are produced.
These procedures may be mechanical, resulting in cell breakage, or depend upon cell lysis, which is caused by adding lysozyme or solvents that affect the cell membrane, or antibiotics or antimetabolites that disrupt or disorganize cell wall growth.
(26 Mar 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 19
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 19
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 19
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 19
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 19
ÅëÇÕ°Ë»ö ¿Ï·á